Researchers have developed a TRBC2-targeted antibody-drug conjugate for T-cell lymphomas and leukemias, addressing half of ...
ONCOLife as a cutting-edge oncology magazine designed for oncologists and health professionals. It has flexible format, available both in print and online formats in the US and EU, ONCOLife is ...
Researchers engineered a retargeted HSV-1 oncolytic virus that selectively infects glioblastoma cells, delivers five ...
BioNTech SE and Bristol Myers Squibb have partnered to co-develop and co-commercialize BNT327, a next-generation bispecific antibody targeting PD-L1 and VEGF-A in over 10 solid tumor indications. The ...
The FDA has granted Breakthrough Device Designation to PreveCol, a blood test for early colorectal cancer detection developed by Amadix. PreveCol excels in identifying precancerous lesions more ...
GSK’s B7-H3 targeted antibody drug conjugate risvutatug rezetecan has received FDA Orphan Drug Designation for small cell lung cancer, supported by early ARTEMIS 001 data showing durable responses in ...
An international PANORAMA study shows that artificial intelligence (AI) can outperform radiologists in detecting pancreatic cancer on routine CT scans. Across 3,440 patients, AI achieved an AUROC of 0 ...
New findings, published in Cellular and Molecular Gastroenterology and Hepatology, show that the transcription factor CREB drives the progression from alcohol-induced pancreatic inflammation to cancer ...
Results from the phase III evERA trial show that giredestrant in combination with everolimus significantly prolonged progression-free survival in ER+, HER2- advanced breast cancer following prior CDK4 ...
Techsomed Medical Technologies announces that the US Food and Drug Administration (FDA) has granted De Novo clearance for its BioTraceIO, an ultrasound-based liver ablation software. This innovative ...
Bayer has launched a first-in-human clinical trial for 225Ac-GPC3 (BAY 3547926), a novel targeted alpha radiopharmaceutical for advanced hepatocellular carcinoma. The therapy uses a GPC3-targeting ...
FDA has approved AKEEGA (niraparib and abiraterone) as the first precision therapy for BRCA2+ metastatic castration-sensitive prostate cancer (mCSPC), following results from the Phase 3 AMPLITUDE ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback